ERBB2 and neoplasm: The group generated circulating tumour cell organoids from patients and identified neuregulin 1 (NRG1)-ERBB2 receptor tyrosine kinase 3 (ERBB3/HER3) signalling as a key survival pathway for cells through multiomics.